Arsenal Bio: Cutting Staff by Half, Not Cells
Arsenal Bio, one of the rare cell therapy companies still swimming in a sea of failed raises, just laid off nearly half its staff. In a sector where funding looks like a unicorn spotted only in biotech myths, Arsenal Bio managed to raise some capital before executing a harsh 50% staff cull. It’s like hosting a party because you found chips, then eating all the guests. This bittersweet survival dance highlights the brutal biotech winter, reminding us that while cells might fight disease, companies clearly don’t fight layoffs. Half the team out, capital precious: Arsenal Bio’s 2024 cell saga, minus the happy ending.
Share the Story
(1 of 3)When your company is 'one of the few able to raise funds' but still chops half your team, your business model is basically survival-of-the-fittest meets corporate Hunger Games.
Arsenal Bio raised cash but still slashed half the staff. Nothing says 'biotech innovation' like 'hope you like unemployment.'
Cell therapy startup Arsenal Bio proves even in science, you’re half as likely to keep your job as to get stem cells.
Source: Statnews | Published: 9/17/2025 | Author: Jason Mast
More Articles in Business
Motorola Razr Flip Phones Finally Told They’re Secure Enough for 2027
America Tries Staying Cool While Secretly Preparing For Wattocalypse
Canada Declares 'No American Goods' After US Says '50% More Please'
US and Canada Start Tariff Edition of Chips Ahoy Costume Party
Zillow Pays Redfin to Not Compete, Then Both Pupils Graduate Antitrust Class
KPMG’s Consulting Business Dies Dramatically While Staff Take a Hike
Man Applies to 200 Jobs with AI's Help, Still Does Own Eyerolling
